{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:18:54Z","timestamp":1785799134896,"version":"3.56.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Program of Xinjiang Production and Construction Corps","award":["2024ZD065"],"award-info":[{"award-number":["2024ZD065"]}]},{"name":"Talent Introduction and Scientific Research Startup Project of Shanghai Fourth People's Hospital, School of Medicine, Tongji University","award":["SYKYQD10101"],"award-info":[{"award-number":["SYKYQD10101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08408-3","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:44:46Z","timestamp":1782467086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Claudin18.2 and the PD-1\/PD-L1 axis in gastric cancer: mechanistic insights and implications for combination immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Yan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-5387","authenticated-orcid":false,"given":"Ping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"8408_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","volume":"406","author":"LM Force","year":"2025","unstructured":"Force LM, Kocarnik JM, May ML, Bhangdia K, Crist A, Penberthy L, et al. The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: A systematic analysis for the global burden of disease study 2023. Lancet. 2025;406:1565\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(25)01635-6.","journal-title":"Lancet"},{"key":"8408_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"8408_CR3","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","volume":"405","author":"R Sundar","year":"2025","unstructured":"Sundar R, Nakayama I, Markar SR, Shitara K, Van Laarhoven HWM, Janjigian YY, et al. Gastric cancer. Lancet. 2025;405:2087\u2013102. https:\/\/doi.org\/10.1016\/S0140-6736(25)00052-2.","journal-title":"Lancet"},{"key":"8408_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"key":"8408_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(16)00175-3.","journal-title":"Lancet Oncol"},{"key":"8408_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"8408_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang Y-J, Di Bartolomeo M, Mandal\u00e0 M, Ryu M-H, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(18)31257-1.","journal-title":"Lancet"},{"key":"8408_CR8","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547.","journal-title":"Clin Cancer Res"},{"key":"8408_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21:354\u201369. https:\/\/doi.org\/10.1038\/s41571-024-00874-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"8408_CR10","doi-asserted-by":"publisher","first-page":"v125","DOI":"10.1093\/annonc\/mdx367.010","volume":"28","author":"C Heinz","year":"2017","unstructured":"Heinz C, Mitnacht-Kraus R, Kreuzberg M, W\u00f6ll S, Sahin U, T\u00fcreci \u00d6. Preclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma. Ann Oncol. 2017;28:v125\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdx367.010.","journal-title":"Ann Oncol"},{"key":"8408_CR11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12885-025-13940-4","volume":"25","author":"NI Kim","year":"2025","unstructured":"Kim NI, Koo JY, Kim SS, Lee JY, Lee JS, Bang HJ, et al. Claudin 18.2 expression profile in primary tumors and their ovarian metastases: implications for targeted therapy. BMC Cancer. 2025;25:540. https:\/\/doi.org\/10.1186\/s12885-025-13940-4.","journal-title":"BMC Cancer"},{"key":"8408_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32:609\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005.","journal-title":"Ann Oncol"},{"key":"8408_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"key":"8408_CR14","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang Y-J, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"8408_CR15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/d41573-024-00172-7","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. FDA approves first claudin-18.2-targeted antibody for gastric cancer. Nat Rev Drug Discov. 2024;23:884. https:\/\/doi.org\/10.1038\/d41573-024-00172-7.","journal-title":"Nat Rev Drug Discov"},{"key":"8408_CR16","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"key":"8408_CR17","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330:2064\u201374. https:\/\/doi.org\/10.1001\/jama.2023.19918.","journal-title":"JAMA"},{"key":"8408_CR18","doi-asserted-by":"publisher","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","volume":"15","author":"X Pang","year":"2023","unstructured":"Pang X, Huang Z, Zhong T, Zhang P, Wang ZM, Xia M, et al. Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs. 2023;15:2180794. https:\/\/doi.org\/10.1080\/19420862.2023.2180794.","journal-title":"MAbs"},{"key":"8408_CR19","doi-asserted-by":"publisher","first-page":"1166040","DOI":"10.3389\/fonc.2023.1166040","volume":"13","author":"T Deng","year":"2023","unstructured":"Deng T, Li D, Yang Y, Wang F, Bai M, Liu R, et al. Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: A retrospective study. Front Oncol. 2023;13:1166040. https:\/\/doi.org\/10.3389\/fonc.2023.1166040.","journal-title":"Front Oncol"},{"key":"8408_CR20","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/2326-6066.CIR-24-1179","volume":"13","author":"M Fang","year":"2025","unstructured":"Fang M, Li Y, Wang P, Wang Y, Wang X, Wa X, et al. METTL3 Inhibition Restores PD-L1 Expression and CD8\u2009+\u2009T-cell Cytotoxic Function in Immunotherapy-Treated Gastric Cancer. Cancer Immunol Res. 2025;13:1037\u201352. https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-1179.","journal-title":"Cancer Immunol Res"},{"key":"8408_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","volume":"36","author":"C Qi","year":"2024","unstructured":"Qi C, Chong X, Zhou T, Ma M, Gong J, Zhang M, et al. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: a retrospective study. Chin J Cancer Res. 2024;36:78\u201389. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2024.01.08.","journal-title":"Chin J Cancer Res"},{"key":"8408_CR22","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8:100762. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100762.","journal-title":"ESMO Open"},{"key":"8408_CR23","doi-asserted-by":"publisher","first-page":"154699","DOI":"10.1016\/j.prp.2023.154699","volume":"248","author":"D Tao","year":"2023","unstructured":"Tao D, Guan B, Li Z, Jiao M, Zhou C, Li H. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer. Pathol Res Pract. 2023;248:154699. https:\/\/doi.org\/10.1016\/j.prp.2023.154699.","journal-title":"Pathol Res Pract"},{"key":"8408_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","volume":"20","author":"K Jia","year":"2022","unstructured":"Jia K, Chen Y, Sun Y, Hu Y, Jiao L, Ma J, et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med. 2022;20:223. https:\/\/doi.org\/10.1186\/s12916-022-02421-1.","journal-title":"BMC Med"},{"key":"8408_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","volume":"100","author":"U Sahin","year":"2018","unstructured":"Sahin U, Schuler M, Richly H, Bauer S, Krilova A, Dechow T, et al. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018;100:17\u201326. https:\/\/doi.org\/10.1016\/j.ejca.2018.05.007.","journal-title":"Eur J Cancer"},{"key":"8408_CR26","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O T\u00fcreci","year":"2019","unstructured":"T\u00fcreci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019;30:1487\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdz199.","journal-title":"Ann Oncol"},{"key":"8408_CR27","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara K, Xu R-H, Ajani JA, Moran D, Guerrero A, Li R, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27:1058\u201368. https:\/\/doi.org\/10.1007\/s10120-024-01518-1.","journal-title":"Gastric Cancer"},{"key":"8408_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/2326-6066.CIR-18-0436","volume":"7","author":"D Zeng","year":"2019","unstructured":"Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7:737\u201350. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0436.","journal-title":"Cancer Immunol Res"},{"key":"8408_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","volume":"23","author":"C Wang","year":"2023","unstructured":"Wang C, Wang Y, Chen J, Wang Y, Pang C, Liang C, et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 2023;23:283. https:\/\/doi.org\/10.1186\/s12876-023-02924-y.","journal-title":"BMC Gastroenterol"},{"key":"8408_CR30","doi-asserted-by":"publisher","first-page":"102015","DOI":"10.1016\/j.ctrv.2020.102015","volume":"86","author":"V Gambardella","year":"2020","unstructured":"Gambardella V, Castillo J, Tarazona N, Gimeno-Valiente F, Mart\u00ednez-Ciarpaglini C, Cabeza-Segura M, et al. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treat Rev. 2020;86:102015. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102015.","journal-title":"Cancer Treat Rev"},{"key":"8408_CR31","doi-asserted-by":"publisher","first-page":"17916","DOI":"10.1038\/s41598-024-68970-y","volume":"14","author":"A Matsuishi","year":"2024","unstructured":"Matsuishi A, Nakajima S, Saito M, Saito K, Fukai S, Tsumuraya H, et al. The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer. Sci Rep. 2024;14:17916. https:\/\/doi.org\/10.1038\/s41598-024-68970-y.","journal-title":"Sci Rep"},{"key":"8408_CR32","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1016\/j.annonc.2025.05.426","volume":"36","author":"M Malla","year":"2025","unstructured":"Malla M, Deshmukh SK, Samec T, Wu S, Xiu J, Akce M, et al. 410P comprehensive molecular and immunological characterization of CLDN18.2 in esophageal and esophagogastric junction carcinoma (EEJC). Ann Oncol. 2025;36:S161. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.426.","journal-title":"Ann Oncol"},{"key":"8408_CR33","doi-asserted-by":"publisher","first-page":"e2413913","DOI":"10.1002\/advs.202413913","volume":"12","author":"X Wang","year":"2025","unstructured":"Wang X, Hui H, Han J, Guo T, Wang Y, Meng L, et al. A CLDN18.2-targeted nanoplatform manipulates magnetic hyperthermia spatiotemporally for synergistic immunotherapy in gastric cancer. Adv Sci (Weinh). 2025;12:e2413913. https:\/\/doi.org\/10.1002\/advs.202413913.","journal-title":"Adv Sci (Weinh)"},{"key":"8408_CR34","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.2022.40.16_suppl.4048","volume":"40","author":"A Lenz","year":"2022","unstructured":"Lenz A, Zeng J, Xiu J, Algaze S, Jayachandran P, Soni S, et al. Claudin 18 (CLDN18) gene expression and related molecular profile in gastric cancer (GC). J Clin Oncol. 2022;40:4048. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4048.","journal-title":"J Clin Oncol"},{"key":"8408_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/biomedicines9040361","volume":"9","author":"A Cruz-Berm\u00fadez","year":"2021","unstructured":"Cruz-Berm\u00fadez A, Laza-Briviesca R, Casarrubios M, Sierra-Rodero B, Provencio M. The role of metabolism in tumor immune evasion: Novel approaches to improve immunotherapy. Biomedicines. 2021;9:361. https:\/\/doi.org\/10.3390\/biomedicines9040361.","journal-title":"Biomedicines"},{"key":"8408_CR36","doi-asserted-by":"publisher","first-page":"1954761","DOI":"10.1080\/2162402X.2021.1954761","volume":"10","author":"Y Park","year":"2021","unstructured":"Park Y, Seo AN, Koh J, Nam SK, Kwak Y, Ahn S-H, et al. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry. Oncoimmunology. 2021;10:1954761. https:\/\/doi.org\/10.1080\/2162402X.2021.1954761.","journal-title":"Oncoimmunology"},{"key":"8408_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fimmu.2019.00071","volume":"10","author":"D Zhang","year":"2019","unstructured":"Zhang D, He W, Wu C, Tan Y, He Y, Xu B, et al. Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer. Front Immunol. 2019;10:71. https:\/\/doi.org\/10.3389\/fimmu.2019.00071.","journal-title":"Front Immunol"},{"key":"8408_CR38","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/jpm11111095","volume":"11","author":"A Pellino","year":"2021","unstructured":"Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, et al. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J Pers Med. 2021;11:1095. https:\/\/doi.org\/10.3390\/jpm11111095.","journal-title":"J Pers Med"},{"key":"8408_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5230\/jgc.2025.25.e3","volume":"25","author":"HS Lee","year":"2025","unstructured":"Lee HS. Spatial and Temporal Tumor Heterogeneity in Gastric Cancer: Discordance of Predictive Biomarkers. J Gastric Cancer. 2025;25:192\u2013209. https:\/\/doi.org\/10.5230\/jgc.2025.25.e3.","journal-title":"J Gastric Cancer"},{"issue":"16suppl","key":"8408_CR40","doi-asserted-by":"publisher","first-page":"e16094","DOI":"10.1200\/JCO.2025.43.16_suppl.e16094","volume":"43","author":"DR Castillo","year":"2025","unstructured":"Castillo DR, Guo M, Kim KJ, Zhong H, Brar G, Wu S, et al. Association of Claudin18.2 expression, PD-L1, and prognostic implications in gastric and gastroesophageal junction cancers. J Clin Oncol. 2025;43(16suppl):e16094. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e16094.","journal-title":"J Clin Oncol"},{"key":"8408_CR41","doi-asserted-by":"publisher","first-page":"e1163462","DOI":"10.1080\/2162402X.2016.1163462","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5:e1163462. https:\/\/doi.org\/10.1080\/2162402X.2016.1163462.","journal-title":"Oncoimmunology"},{"key":"8408_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jare.2023.04.013","volume":"57","author":"Y Lv","year":"2024","unstructured":"Lv Y, Tian W, Teng Y, Wang P, Zhao Y, Li Z, et al. Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression. J Adv Res. 2024;57:149\u201362. https:\/\/doi.org\/10.1016\/j.jare.2023.04.013.","journal-title":"J Adv Res"},{"key":"8408_CR43","doi-asserted-by":"publisher","first-page":"e15079","DOI":"10.1200\/jco.2015.33.15_suppl.e15079","volume":"33","author":"U Sahin","year":"2015","unstructured":"Sahin U, Al-Batran S-E, Hozaeel W, Zvirbule Z, Freiberg-Richter J, Lordick F, et al. IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): clinical activity and safety data from the PILOT phase I trial. J Clin Oncol. 2015;33:e15079. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.e15079.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8408_CR44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-023-01463-y","volume":"8","author":"X Wang","year":"2023","unstructured":"Wang X, Liu L, Yue T, Sun Z, Bae J, Tseng K-F, et al. Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8 T cells. Signal Transduct Target Ther. 2023;8(1):268. https:\/\/doi.org\/10.1038\/s41392-023-01463-y.","journal-title":"Signal Transduct Target Ther"},{"key":"8408_CR45","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340. https:\/\/doi.org\/10.1172\/JCI91190.","journal-title":"J Clin Invest"},{"key":"8408_CR46","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","volume":"4","author":"T Bald","year":"2014","unstructured":"Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, et al. Immune cell\u2013poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014;4:674\u201387. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0458.","journal-title":"Cancer Discov"},{"key":"8408_CR47","doi-asserted-by":"publisher","first-page":"e93886","DOI":"10.1371\/journal.pone.0093886","volume":"9","author":"D Gao","year":"2014","unstructured":"Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS ONE. 2014;9:e93886. https:\/\/doi.org\/10.1371\/journal.pone.0093886.","journal-title":"PLoS ONE"},{"key":"8408_CR48","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/cancers17060998","volume":"17","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Li Y, Wang S, Han J, Lu M, Xu Y, et al. CAR-\u03b3\u03b4 T cells targeting Claudin18.2 show superior cytotoxicity against solid tumor compared to traditional CAR-\u03b1\u03b2 T cells. Cancers. 2025;17:998. https:\/\/doi.org\/10.3390\/cancers17060998.","journal-title":"Cancers"},{"key":"8408_CR49","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nm.4466","volume":"24","author":"C Krieg","year":"2018","unstructured":"Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24:144\u201353. https:\/\/doi.org\/10.1038\/nm.4466.","journal-title":"Nat Med"},{"key":"8408_CR50","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.21873\/anticanres.15110","volume":"41","author":"KS Rallis","year":"2021","unstructured":"Rallis KS, Corrigan AE, Dadah H, George AM, Keshwara SM, Sideris M, et al. Cytokine-based cancer immunotherapy: Challenges and opportunities for IL-10. Anticancer Res. 2021;41:3247\u201352. https:\/\/doi.org\/10.21873\/anticanres.15110.","journal-title":"Anticancer Res"},{"key":"8408_CR51","doi-asserted-by":"publisher","first-page":"2300846","DOI":"10.1080\/19490976.2023.2300846","volume":"16","author":"SY Lee","year":"2024","unstructured":"Lee SY, Jhun J, Woo JS, Lee KH, Hwang S-H, Moon J, et al. Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer. Gut Microbes. 2024;16:2300846. https:\/\/doi.org\/10.1080\/19490976.2023.2300846.","journal-title":"Gut Microbes"},{"key":"8408_CR52","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.autrev.2020.102590","volume":"19","author":"P Triggianese","year":"2020","unstructured":"Triggianese P, Novelli L, Galdiero MR, Chimenti MS, Conigliaro P, Perricone R, et al. Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. Autoimmun Rev. 2020;19:102590. https:\/\/doi.org\/10.1016\/j.autrev.2020.102590.","journal-title":"Autoimmun Rev"},{"key":"8408_CR53","doi-asserted-by":"publisher","first-page":"684642","DOI":"10.3389\/fimmu.2021.684642","volume":"12","author":"M Bell","year":"2021","unstructured":"Bell M, Gottschalk S. Engineered cytokine signaling to improve CAR T cell effector function. Front Immunol. 2021;12:684642. https:\/\/doi.org\/10.3389\/fimmu.2021.684642.","journal-title":"Front Immunol"},{"key":"8408_CR54","doi-asserted-by":"publisher","first-page":"e15074","DOI":"10.1200\/jco.2024.42.16_suppl.e15074","volume":"42","author":"J Zhang","year":"2024","unstructured":"Zhang J, Liu J. A phase 1 study of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated (TAA) CD8 T cells in patients with advanced solid tumors. J Clin Oncol. 2024;42:e15074. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.e15074.","journal-title":"J Clin Oncol"},{"key":"8408_CR55","doi-asserted-by":"publisher","first-page":"TPS4196","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4196","volume":"41","author":"J Liu","year":"2023","unstructured":"Liu J, L&L Team. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8\u2009+\u2009t CELLS in patients with advanced solid tumors. J Clin Oncol. 2023;41:TPS4196. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS4196.","journal-title":"J Clin Oncol"},{"key":"8408_CR56","doi-asserted-by":"publisher","first-page":"934221","DOI":"10.3389\/fimmu.2022.934221","volume":"13","author":"H Pan","year":"2022","unstructured":"Pan H, Pan J, Wu J. Development and validation of a cancer-associated fibroblast-derived lncRNA signature for predicting clinical outcomes in colorectal cancer. Front Immunol. 2022;13:934221. https:\/\/doi.org\/10.3389\/fimmu.2022.934221.","journal-title":"Front Immunol"},{"key":"8408_CR57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol Cancer. 2021;20:131. https:\/\/doi.org\/10.1186\/s12943-021-01428-1.","journal-title":"Mol Cancer"},{"key":"8408_CR58","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41575-019-0115-0","volume":"16","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi H, Enomoto A, Woods SL, Burt AD, Takahashi M, Worthley DL. Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2019;16:282\u201395. https:\/\/doi.org\/10.1038\/s41575-019-0115-0.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8408_CR59","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174\u201386. https:\/\/doi.org\/10.1038\/s41568-019-0238-1.","journal-title":"Nat Rev Cancer"},{"key":"8408_CR60","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12964-023-01406-8","volume":"22","author":"S Liu","year":"2024","unstructured":"Liu S, Zhang Z, Jiang L, Zhang M, Zhang C, Shen L. Claudin-18.2 mediated interaction of gastric cancer cells and cancer-associated fibroblasts drives tumor progression. Cell Commun Signal. 2024;22:27. https:\/\/doi.org\/10.1186\/s12964-023-01406-8.","journal-title":"Cell Commun Signal"},{"key":"8408_CR61","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdx367.012","volume":"28","author":"R Mitnacht-Kraus","year":"2017","unstructured":"Mitnacht-Kraus R, Kreuzberg M, Utsch M, Sahin U, T\u00fcreci \u00d6. Preclinical characterization of IMAB362 for the treatment of gastric carcinoma. Ann Oncol. 2017;28:v126. https:\/\/doi.org\/10.1093\/annonc\/mdx367.012.","journal-title":"Ann Oncol"},{"key":"8408_CR62","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1007\/s00432-022-04459-3","volume":"149","author":"F Lordick","year":"2023","unstructured":"Lordick F, Thuss-Patience P, Bitzer M, Maurus D, Sahin U, T\u00fcreci \u00d6. Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. J Cancer Res Clin Oncol. 2023;149:5937\u201350. https:\/\/doi.org\/10.1007\/s00432-022-04459-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"8408_CR63","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10120-012-0210-1","volume":"16","author":"H Saito","year":"2013","unstructured":"Saito H, Takaya S, Osaki T, Ikeguchi M. Increased apoptosis and elevated fas expression in circulating natural killer cells in gastric cancer patients. Gastric Cancer. 2013;16:473\u20139. https:\/\/doi.org\/10.1007\/s10120-012-0210-1.","journal-title":"Gastric Cancer"},{"key":"8408_CR64","doi-asserted-by":"publisher","first-page":"e1069936","DOI":"10.1080\/2162402X.2015.1069936","volume":"5","author":"T Li","year":"2016","unstructured":"Li T, Zhang Q, Jiang Y, Yu J, Hu Y, Mou T, et al. Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2. Oncoimmunology. 2016;5:e1069936. https:\/\/doi.org\/10.1080\/2162402X.2015.1069936.","journal-title":"Oncoimmunology"},{"key":"8408_CR65","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/2767-9764.CRC-22-0216","volume":"2","author":"H Konno","year":"2022","unstructured":"Konno H, Lin T, Wu R, Dai X, Li S, Wang G, et al. ZL-1211 exhibits robust antitumor activity by enhancing ADCC and activating NK cell\u2013mediated inflammation in CLDN18.2-high and -low expressing gastric cancer models. Cancer Res Commun. 2022;2:937\u201350. https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0216.","journal-title":"Cancer Res Commun"},{"key":"8408_CR66","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","volume":"10","author":"P Singh","year":"2017","unstructured":"Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol. 2017;10:105. https:\/\/doi.org\/10.1186\/s13045-017-0473-4.","journal-title":"J Hematol Oncol"},{"key":"8408_CR67","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3390\/medicina58101411","volume":"58","author":"H-C Yu","year":"2022","unstructured":"Yu H-C, Huang K-Y, Lu M-C, Huang Tseng H-Y, Liu S-Q, Lai N-S, et al. HLA-B*27 heavy chain homo-oligomers promote the cytotoxicity of NK cells via activation of PI3K\/AKT signaling. Medicina. 2022;58:1411. https:\/\/doi.org\/10.3390\/medicina58101411.","journal-title":"Medicina"},{"key":"8408_CR68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura K, Teh JL, Okayama H, Shiraishi K, Kua L, Koh V, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018;109:43\u201353. https:\/\/doi.org\/10.1111\/cas.13424.","journal-title":"Cancer Sci"},{"key":"8408_CR69","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.1096\/fasebj.29.1_supplement.999.6","volume":"29","author":"Y Zheng","year":"2015","unstructured":"Zheng Y, Wu J, Muthupalani S, Wang Y, Ang L-H, Fox J, et al. Attenuation of claudin-18 in mouse stomach promotes the development of intramucosal carcinoma. FASEB J. 2015;29:9996. https:\/\/doi.org\/10.1096\/fasebj.29.1_supplement.999.6.","journal-title":"FASEB J"},{"key":"8408_CR70","doi-asserted-by":"publisher","first-page":"S873","DOI":"10.1016\/j.annonc.2023.09.1472","volume":"34","author":"X Qian","year":"2023","unstructured":"Qian X, Teng F, Guo H, Yao X, Shi L, Wu Y, et al. 1560P osemitamab (TST001): An ADCC enhanced humanized anti-CLDN18.2 mab, demonstrated improved efficacy in combination with anti-PD-L1\/PD-1 mab and oxaliplatin\/5-FU in preclinical tumor models. Ann Oncol. 2023;34:S873. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1472.","journal-title":"Ann Oncol"},{"key":"8408_CR71","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37. https:\/\/doi.org\/10.1126\/scitranslmed.3003689.","journal-title":"Sci Transl Med"},{"key":"8408_CR72","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.ijrobp.2022.10.028","volume":"115","author":"S Nakajima","year":"2023","unstructured":"Nakajima S, Mimura K, Kaneta A, Saito K, Katagata M, Okayama H, et al. Radiation-induced remodeling of the tumor microenvironment through tumor cell-intrinsic expression of cGAS-STING in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2023;115:957\u201371. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.10.028.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"8408_CR73","doi-asserted-by":"publisher","first-page":"G336","DOI":"10.1152\/ajpgi.00328.2007","volume":"294","author":"K Yano","year":"2008","unstructured":"Yano K, Imaeda T, Niimi T. Transcriptional activation of the human claudin-18 gene promoter through two AP-1 motifs in PMA-stimulated MKN45 gastric cancer cells. Am J Physiol Gastrointest Liver Physiol. 2008;294:G336\u201343. https:\/\/doi.org\/10.1152\/ajpgi.00328.2007.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"8408_CR74","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1369\/0022155411420569","volume":"59","author":"M Tanaka","year":"2011","unstructured":"Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S, et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem. 2011;59:942\u201352. https:\/\/doi.org\/10.1369\/0022155411420569.","journal-title":"J Histochem Cytochem"},{"key":"8408_CR75","doi-asserted-by":"publisher","first-page":"1132319","DOI":"10.3389\/fonc.2023.1132319","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen J, Xu Z, Hu C, Zhang S, Zi M, Yuan L, et al. Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications. Front Oncol. 2023;13:1132319. https:\/\/doi.org\/10.3389\/fonc.2023.1132319.","journal-title":"Front Oncol"},{"key":"8408_CR76","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/jcb.23095","volume":"112","author":"T Ito","year":"2011","unstructured":"Ito T, Kojima T, Yamaguchi H, Kyuno D, Kimura Y, Imamura M, et al. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. J Cell Biochem. 2011;112:1761\u201372. https:\/\/doi.org\/10.1002\/jcb.23095.","journal-title":"J Cell Biochem"},{"key":"8408_CR77","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","volume":"481","author":"O T\u00fcreci","year":"2011","unstructured":"T\u00fcreci O, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011;481:83\u201392. https:\/\/doi.org\/10.1016\/j.gene.2011.04.007.","journal-title":"Gene"},{"key":"8408_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000511243","volume":"102","author":"G Usui","year":"2020","unstructured":"Usui G, Matsusaka K, Mano Y, Urabe M, Funata S, Fukayama M, et al. DNA methylation and genetic aberrations in gastric cancer. Digestion. 2020;102:25\u201332. https:\/\/doi.org\/10.1159\/000511243.","journal-title":"Digestion"},{"key":"8408_CR79","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1073\/pnas.0501076102","volume":"102","author":"X Zhang","year":"2005","unstructured":"Zhang X, Odom DT, Koo S-H, Conkright MD, Canettieri G, Best J, et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A. 2005;102:4459\u201364. https:\/\/doi.org\/10.1073\/pnas.0501076102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8408_CR80","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther. 2021;6(1):412. https:\/\/doi.org\/10.1038\/s41392-021-00823-w.","journal-title":"Signal Transduct Target Ther"},{"key":"8408_CR81","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s1074-7613(04)00051-2","volume":"20","author":"X Zhang","year":"2004","unstructured":"Zhang X, Schwartz J-CD, Guo X, Bhatia S, Cao E, Chen L, et al. Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1. Immunity. 2004;20:337\u201347. https:\/\/doi.org\/10.1016\/s1074-7613(04)00051-2.","journal-title":"Immunity"},{"key":"8408_CR82","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/jci99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault M-C, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest. 2018;128:4654\u201368. https:\/\/doi.org\/10.1172\/jci99317.","journal-title":"J Clin Invest"},{"key":"8408_CR83","doi-asserted-by":"publisher","first-page":"15419","DOI":"10.1073\/pnas.1206370109","volume":"109","author":"G Xiao","year":"2012","unstructured":"Xiao G, Deng A, Liu H, Ge G, Liu X. Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. Proc Natl Acad Sci U S A. 2012;109:15419\u201324. https:\/\/doi.org\/10.1073\/pnas.1206370109.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8408_CR84","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1038\/s44321-024-00120-3","volume":"16","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang H, Shi T, Song X, Zhang X, Zhang Y, et al. Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer. EMBO Mol Med. 2024;16:2170\u201387. https:\/\/doi.org\/10.1038\/s44321-024-00120-3.","journal-title":"EMBO Mol Med"},{"key":"8408_CR85","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2017.05.033","volume":"403","author":"K Takasawa","year":"2017","unstructured":"Takasawa K, Takasawa A, Osanai M, Aoyama T, Ono Y, Kono T, et al. Claudin-18 coupled with EGFR\/ERK signaling contributes to the malignant potentials of bile duct cancer. Cancer Lett. 2017;403:66\u201373. https:\/\/doi.org\/10.1016\/j.canlet.2017.05.033.","journal-title":"Cancer Lett"},{"key":"8408_CR86","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/ITT.S494696","volume":"14","author":"Y Wu","year":"2025","unstructured":"Wu Y, Tian J, Zhou Y, Zhang R, Gao X, Luo L. Development and Characterization of 4A7: A High-Affinity Monoclonal Antibody Targeting Claudin18.2. Immunotargets Ther. 2025;14:189\u2013203. https:\/\/doi.org\/10.2147\/ITT.S494696.","journal-title":"Immunotargets Ther"},{"key":"8408_CR87","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jphs.2024.04.004","volume":"155","author":"T Nishibata","year":"2024","unstructured":"Nishibata T, Weng J, Omori K, Sato Y, Nakazawa T, Suzuki T, et al. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models. J Pharmacol Sci. 2024;155:84\u201393. https:\/\/doi.org\/10.1016\/j.jphs.2024.04.004.","journal-title":"J Pharmacol Sci"},{"key":"8408_CR88","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.21.01862","volume":"40","author":"JJ Zhao","year":"2022","unstructured":"Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, et al. Low programmed death-ligand 1\u2013expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40:392\u2013402. https:\/\/doi.org\/10.1200\/JCO.21.01862.","journal-title":"J Clin Oncol"},{"key":"8408_CR89","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.2024.42.16_suppl.4048","volume":"42","author":"X Zhang","year":"2024","unstructured":"Zhang X, Guo Z, Zhang J, Guo W, Sun M, Xu N, et al. First-line osemitamab (TST001) plus nivolumab and capox for advanced g\/GEJ cancer (TranStar102): Results of cohort G from a phase I\/IIa study. J Clin Oncol. 2024;42:4048. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4048.","journal-title":"J Clin Oncol"},{"key":"8408_CR90","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/JCO.2024.42.3_suppl.317","volume":"42","author":"Z Peng","year":"2024","unstructured":"Peng Z, Shen L, He Y, Chen J, Hickingbottom B, Lu J. A phase ib\/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric\/gastro-esophageal junction (G\/GEJ) adenocarcinoma. J Clin Oncol. 2024;42:317. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.317.","journal-title":"J Clin Oncol"},{"key":"8408_CR91","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2025.43.16_suppl.4032","volume":"43","author":"J Gong","year":"2025","unstructured":"Gong J, Liu D, Guo Z, Zhang J, Guo W, Sun M, et al. First-line osemitamab (TST001) plus nivolumab and CAPOX for advanced G\/GEJ cancer (TranStar102): updated results of cohort G from a phase I\/IIa study. J Clin Oncol. 2025;43:4032. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4032.","journal-title":"J Clin Oncol"},{"key":"8408_CR92","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: Current challenges and potential strategies. J Hematol Oncol. 2024;17:105. https:\/\/doi.org\/10.1186\/s13045-024-01625-7.","journal-title":"J Hematol Oncol"},{"key":"8408_CR93","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189\u201398. https:\/\/doi.org\/10.1038\/s41591-022-01800-8.","journal-title":"Nat Med"},{"key":"8408_CR94","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30:2224\u201334. https:\/\/doi.org\/10.1038\/s41591-024-03037-z.","journal-title":"Nat Med"},{"key":"8408_CR95","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41416-025-03015-3","volume":"132","author":"J Li","year":"2025","unstructured":"Li J, Tao M, Liu L, Liu C, Ma M, Liu D, et al. Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer. Br J Cancer. 2025;132:1167\u201376. https:\/\/doi.org\/10.1038\/s41416-025-03015-3.","journal-title":"Br J Cancer"},{"key":"8408_CR96","doi-asserted-by":"publisher","first-page":"e16381","DOI":"10.1200\/JCO.2025.43.16_suppl.e16381","volume":"43","author":"S Yang","year":"2025","unstructured":"Yang S, Wu K, Wang J, Kong X, Shi Z, Wang H, et al. MSLN and CLDN18.2 dual-target CAR-T therapy: Enhancing cancer treatment with improved efficacy and safety. J Clin Oncol. 2025;43:e16381. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e16381.","journal-title":"J Clin Oncol"},{"key":"8408_CR97","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1016\/j.annonc.2024.05.445","volume":"35","author":"K Wu","year":"2024","unstructured":"Wu K, Yang S, Shi Z, Wang H, Li X, He X. 531P enhanced antitumor efficacy and safety through a novel CAR-T strategy targeting MSLN and CLDN18.2. Ann Oncol. 2024;35:S211. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.445.","journal-title":"Ann Oncol"},{"key":"8408_CR98","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1158\/1538-7445.AM2025-2942","volume":"85","author":"RF Fleuranvil","year":"2025","unstructured":"Fleuranvil RF, Rustgi N, James M, Hammer Z, Ryan TJ, Reyes J, et al. Abstract 2942: Efficacy of a claudin 18.2\/TGF\u03b2 bi-specific CAR-T in preclinical mouse models of gastric cancer. Cancer Res. 2025;85:2942. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-2942.","journal-title":"Cancer Res"},{"key":"8408_CR99","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s13402-025-01066-5","volume":"48","author":"M Sun","year":"2025","unstructured":"Sun M, Bian L, Wang H, Liu X, Li Y, Wu Z, et al. Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor. Cell Oncol. 2025;48:1299\u2013315. https:\/\/doi.org\/10.1007\/s13402-025-01066-5.","journal-title":"Cell Oncol"},{"key":"8408_CR100","doi-asserted-by":"publisher","unstructured":"Wang C, Wang Q, Gong Y, Liu T, Gao F, Xue G, et al. 331 a novel allogeneic anti-CLDN18.2-specific CAR-NK cell therapy in treating gastric cancer. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0331.","DOI":"10.1136\/jitc-2024-SITC2024.0331"},{"key":"8408_CR101","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s12275-024-00133-0","volume":"62","author":"HJ Lee","year":"2024","unstructured":"Lee HJ, Hwang SJ, Jeong EH, Chang MH. Genetically engineered CLDN18.2 CAR-T cells expressing synthetic PD1\/CD28 fusion receptors produced using a lentiviral vector. J Microbiol. 2024;62:555\u201368. https:\/\/doi.org\/10.1007\/s12275-024-00133-0.","journal-title":"J Microbiol"},{"key":"8408_CR102","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12967-025-06276-x","volume":"23","author":"Z Wu","year":"2025","unstructured":"Wu Z, Wang H, Zheng Z, Lin Y, Bian L, Geng H, et al. IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment. J Transl Med. 2025;23:275. https:\/\/doi.org\/10.1186\/s12967-025-06276-x.","journal-title":"J Transl Med"},{"key":"8408_CR103","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s42764-025-00149-9","volume":"6","author":"W Zhang","year":"2025","unstructured":"Zhang W, Zeng M, Ma X, Chen J, Li Y, Yu L. Autocrine p40 enhances the efficacy of CLDN18.2 CAR-T cells in gastrointestinal cancer. Genome Instab Dis. 2025;6:63\u201379. https:\/\/doi.org\/10.1007\/s42764-025-00149-9.","journal-title":"Genome Instab Dis"},{"key":"8408_CR104","doi-asserted-by":"publisher","unstructured":"Munguia ML, Reyes J, Foord O, BenDavid E, Cui J. 298 therapeutic potential of IMPT-601, a Claudin18.2\/TGF-\u03b2 bispecific CAR, against gastric cancer. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0298.","DOI":"10.1136\/jitc-2024-SITC2024.0298"},{"key":"8408_CR105","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.trsl.2025.08.002","volume":"283","author":"M He","year":"2025","unstructured":"He M, Ge L, Hui H, Zhou Y, Tang Y, Shen L, et al. Noninvasive in vivo tracking of SPIONs-labeled CLDN18.2-targeted CAR-T cells in gastric cancer via magnetic particle imaging. Transl Res. 2025;283:3\u201312. https:\/\/doi.org\/10.1016\/j.trsl.2025.08.002.","journal-title":"Transl Res"},{"key":"8408_CR106","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2023.06.037","volume":"165","author":"Y Xu","year":"2023","unstructured":"Xu Y, Fu J, Henderson M, Lee F, Jurcak N, Henn A, et al. CLDN18.2 BiTE engages effector and regulatory T cells for antitumor immune response in preclinical models of pancreatic cancer. Gastroenterology. 2023;165:1219\u201332. https:\/\/doi.org\/10.1053\/j.gastro.2023.06.037.","journal-title":"Gastroenterology"},{"key":"8408_CR107","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1200\/JCO.2024.42.16_suppl.2519","volume":"42","author":"L Zheng","year":"2024","unstructured":"Zheng L, Ruihong D, Jieer Y, Xu Q, Guo Z, Hu C, et al. Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2\/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study. J Clin Oncol. 2024;42:2519. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2519.","journal-title":"J Clin Oncol"},{"key":"8408_CR108","doi-asserted-by":"publisher","first-page":"e006704","DOI":"10.1136\/jitc-2023-006704","volume":"11","author":"J Gao","year":"2023","unstructured":"Gao J, Wang Z, Jiang W, Zhang Y, Meng Z, Niu Y, et al. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. J Immunother Cancer. 2023;11:e006704. https:\/\/doi.org\/10.1136\/jitc-2023-006704.","journal-title":"J Immunother Cancer"},{"key":"8408_CR109","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1200\/JCO.2022.40.16_suppl.2568","volume":"40","author":"J Gong","year":"2022","unstructured":"Gong J, Shen L, Hou J, Chen X, Yu Q, Zheng Y, et al. Safety results of Q-1802, a Claudin18.2\/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study. J Clin Oncol. 2022;40:2568. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2568.","journal-title":"J Clin Oncol"},{"key":"8408_CR110","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/JCO.2023.41.4_suppl.382","volume":"41","author":"W Yk","year":"2023","unstructured":"Yk W, Gong J, Sun Y, Zhang J, Ni S, Hou J, et al. Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2\/PD-L1 bsABs, in patients with relapsed or refractory solid tumors. J Clin Oncol. 2023;41:382. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.382.","journal-title":"J Clin Oncol"},{"key":"8408_CR111","doi-asserted-by":"publisher","first-page":"e009710","DOI":"10.1136\/jitc-2024-009710","volume":"12","author":"Y Dong","year":"2024","unstructured":"Dong Y, Zhang Z, Luan S, Zheng M, Wang Z, Chen Y, et al. Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses. J Immunother Cancer. 2024;12:e009710. https:\/\/doi.org\/10.1136\/jitc-2024-009710.","journal-title":"J Immunother Cancer"},{"key":"8408_CR112","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.2025.43.16_suppl.3034","volume":"43","author":"J Yu","year":"2025","unstructured":"Yu J, Sun Y, Liu T, Guo Z, Ying J, Sun M, et al. Efficacy and safety of XNW27011, a claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with claudin 18.2 positive gastric\/gastroesophageal junction cancer: results from ongoing phase I\/II study. J Clin Oncol. 2025;43:3034. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3034.","journal-title":"J Clin Oncol"},{"key":"8408_CR113","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"D-Y Ruan","year":"2025","unstructured":"Ruan D-Y, Liu F-R, Wei X-L, Luo S-X, Zhuang Z-X, Wang Z-N, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26:227\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(24)00636-3.","journal-title":"Lancet Oncol"},{"key":"8408_CR114","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2025.43.4_suppl.456","volume":"43","author":"J Ma","year":"2025","unstructured":"Ma J, Cao D, Zhao Q, Mendis SR, Coward J, Lv J, et al. Safety and preliminary efficacy of ATG-022 in patients with advanced\/metastatic gastric cancer (CLINCH). J Clin Oncol. 2025;43:456. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.456.","journal-title":"J Clin Oncol"},{"key":"8408_CR115","doi-asserted-by":"publisher","first-page":"TPS4201","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4201","volume":"43","author":"L Shen","year":"2025","unstructured":"Shen L, Shitara K, Mei Q, Li C, Wei J, Xie X, et al. A multiregional, randomized, controlled, open-label, phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G\/GEJA): trial in progress. J Clin Oncol. 2025;43:TPS4201. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS4201.","journal-title":"J Clin Oncol"},{"key":"8408_CR116","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1200\/JCO.2025.43.16_suppl.4039","volume":"43","author":"H Jiang","year":"2025","unstructured":"Jiang H, Huang M, Wan L, Markman B, Pan H, Bai C, et al. Efficacy and safety of LM-302 (anti-claudin 18.2 ADC) in combination with anti-PD-1 therapy for advanced gastric, gastroesophageal junction cancer and esophageal adenocarcinoma: early-phase study results. J Clin Oncol. 2025;43:4039. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4039.","journal-title":"J Clin Oncol"},{"key":"8408_CR117","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41416-025-02981-y","volume":"132","author":"C Tsutsumi","year":"2025","unstructured":"Tsutsumi C, Ohuchida K, Yamada Y, Shimada Y, Imamura M, Son K, et al. Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment. Br J Cancer. 2025;132:793\u2013804. https:\/\/doi.org\/10.1038\/s41416-025-02981-y.","journal-title":"Br J Cancer"},{"key":"8408_CR118","doi-asserted-by":"publisher","first-page":"e012683","DOI":"10.1136\/jitc-2025-012683","volume":"13","author":"SH Lim","year":"2025","unstructured":"Lim SH, Kuwata T, An M, Hong JY, Kim ST, Matsubara Y, et al. Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy. J Immunother Cancer. 2025;13:e012683. https:\/\/doi.org\/10.1136\/jitc-2025-012683.","journal-title":"J Immunother Cancer"},{"key":"8408_CR119","doi-asserted-by":"publisher","first-page":"5386","DOI":"10.1158\/1538-7445.AM2020-5386","volume":"80","author":"X Chong","year":"2020","unstructured":"Chong X, Fan L, Qi C, Gong J, Peng Z, Liu D, et al. Abstract 5386: In situ detection of CLDN18.2 RNA in circulating tumor cells in gastrointestinal cancer. Cancer Res. 2020;80:5386. https:\/\/doi.org\/10.1158\/1538-7445.AM2020-5386.","journal-title":"Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08408-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:58:45Z","timestamp":1782475125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08408-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8408"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08408-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"826"}}